tetano
Editor, Senior Moderator
BMC Pulm Med
. 2022 Mar 24;22(1):101.
doi: 10.1186/s12890-022-01900-8.
One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis
Anke Jaudszus[SUP] 1 [/SUP], Mariya Pavlova[SUP] 1 [/SUP], Marius Rasche[SUP] 1 [/SUP], Michael Baier[SUP] 2 [/SUP], Anne Moeser[SUP] 3 [/SUP], Michael Lorenz[SUP] 4 [/SUP]
Affiliations
Abstract
Background: In Germany, the first case of coronavirus disease 2019 (COVID-19) was registered on 28 January 2020. By February 2021, the third wave of the pandemic began. So far, only few data are available on the SARS-CoV-2 prevalence and the clinical impact of an infection in patients with cystic fibrosis (CF).
Methods: From February 2020 until March 2021, we screened 156 CF patients for anti-SARS-CoV-2 IgG antibodies (serology) and the presence of SARS-CoV-2 in deep throat saliva or nasopharyngeal swabs (molecular testing). From patients with confirmed SARS-CoV-2 infection, we recorded symptoms and collected clinical data.
Results: In total, 13 patients (8.3%) were tested positive for SARS-CoV-2 infection, most of them during the second and the beginning third wave of the pandemic. Ten positive tested patients described symptoms linked to COVID-19. The most common symptom was cough followed by fatigue and headache. SARS-CoV-2 infection did not impair lung function. No positive tested patient needed to be hospitalized.
Conclusions: SARS-CoV-2 infections in patients with CF are not as rare as initially anticipated, as frequent testing revealed. However, infected patients did not experience more severe clinical courses or worse clinical outcome. Our observation is in line with published reports indicating that individuals with CF are not at higher risk for severe COVID-19.
. 2022 Mar 24;22(1):101.
doi: 10.1186/s12890-022-01900-8.
One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis
Anke Jaudszus[SUP] 1 [/SUP], Mariya Pavlova[SUP] 1 [/SUP], Marius Rasche[SUP] 1 [/SUP], Michael Baier[SUP] 2 [/SUP], Anne Moeser[SUP] 3 [/SUP], Michael Lorenz[SUP] 4 [/SUP]
Affiliations
- PMID: 35331203
- DOI: 10.1186/s12890-022-01900-8
Abstract
Background: In Germany, the first case of coronavirus disease 2019 (COVID-19) was registered on 28 January 2020. By February 2021, the third wave of the pandemic began. So far, only few data are available on the SARS-CoV-2 prevalence and the clinical impact of an infection in patients with cystic fibrosis (CF).
Methods: From February 2020 until March 2021, we screened 156 CF patients for anti-SARS-CoV-2 IgG antibodies (serology) and the presence of SARS-CoV-2 in deep throat saliva or nasopharyngeal swabs (molecular testing). From patients with confirmed SARS-CoV-2 infection, we recorded symptoms and collected clinical data.
Results: In total, 13 patients (8.3%) were tested positive for SARS-CoV-2 infection, most of them during the second and the beginning third wave of the pandemic. Ten positive tested patients described symptoms linked to COVID-19. The most common symptom was cough followed by fatigue and headache. SARS-CoV-2 infection did not impair lung function. No positive tested patient needed to be hospitalized.
Conclusions: SARS-CoV-2 infections in patients with CF are not as rare as initially anticipated, as frequent testing revealed. However, infected patients did not experience more severe clinical courses or worse clinical outcome. Our observation is in line with published reports indicating that individuals with CF are not at higher risk for severe COVID-19.